Dasatinib or high-dose imatinib for chronic-phase chronic myeloid leukemia after failure of first-line imatinib: A randomized phase 2 trial

Hagop Kantarjian, Ricardo Pasquini, Nelson Hamerschlak, Philippe Rousselot, Jerzy Holowiecki, Saengsuree Jootar, Tadeusz Robak, Nina Khoroshko, T. Masszi, Aleksander Skotnicki, Andrzej Hellmann, Andrey Zaritsky, Anatoly Golenkov, Jerald Radich, Timothy Hughes, Athena Countouriotis, Neil Shah

Research output: Article

319 Citations (Scopus)

Abstract

Therapeutic options for chronic myelogenous leukemia (CML) resistant to 400 to 600 mg imatinib are limited. Escalating imatinib doses may overcome resistance. Dasatinib, a significantly more potent inhibitor of BCR-ABL, is safe and effective in this population. Patients with imatinib-resistant chronic-phase (CP) CML were randomized 2:1 to 140 mg dasatinib (n = 101) or 800 mg imatinib (n = 49). With a median follow up of 15 months, complete hematologic responses were observed in 93% and 82% of patients receiving dasatinib and high-dose imatinib (P = .034), respectively. Dasatinib resulted in higher major cytogenetic response rates (52%) than high-dose imatinib (33%) (P = .023); this included complete cytogenetic response in 40% and 16% (P = .004). Major molecular responses were also more frequent with dasatinib (16% versus 4%; P = 0.038). Treatment failure (hazard ratio [HR], 0.16; P <.001) and progression-free survival (HR, 0.14;P

Original languageEnglish
Pages (from-to)5143-5150
Number of pages8
JournalBlood
Volume109
Issue number12
DOIs
Publication statusPublished - jún. 15 2007

Fingerprint

Leukemia, Myeloid, Chronic Phase
Cytogenetics
Hazards
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Treatment Failure
Disease-Free Survival
Imatinib Mesylate
Dasatinib
Population

ASJC Scopus subject areas

  • Hematology

Cite this

Kantarjian, H., Pasquini, R., Hamerschlak, N., Rousselot, P., Holowiecki, J., Jootar, S., ... Shah, N. (2007). Dasatinib or high-dose imatinib for chronic-phase chronic myeloid leukemia after failure of first-line imatinib: A randomized phase 2 trial. Blood, 109(12), 5143-5150. https://doi.org/10.1182/blood-2006-11-056028

Dasatinib or high-dose imatinib for chronic-phase chronic myeloid leukemia after failure of first-line imatinib : A randomized phase 2 trial. / Kantarjian, Hagop; Pasquini, Ricardo; Hamerschlak, Nelson; Rousselot, Philippe; Holowiecki, Jerzy; Jootar, Saengsuree; Robak, Tadeusz; Khoroshko, Nina; Masszi, T.; Skotnicki, Aleksander; Hellmann, Andrzej; Zaritsky, Andrey; Golenkov, Anatoly; Radich, Jerald; Hughes, Timothy; Countouriotis, Athena; Shah, Neil.

In: Blood, Vol. 109, No. 12, 15.06.2007, p. 5143-5150.

Research output: Article

Kantarjian, H, Pasquini, R, Hamerschlak, N, Rousselot, P, Holowiecki, J, Jootar, S, Robak, T, Khoroshko, N, Masszi, T, Skotnicki, A, Hellmann, A, Zaritsky, A, Golenkov, A, Radich, J, Hughes, T, Countouriotis, A & Shah, N 2007, 'Dasatinib or high-dose imatinib for chronic-phase chronic myeloid leukemia after failure of first-line imatinib: A randomized phase 2 trial', Blood, vol. 109, no. 12, pp. 5143-5150. https://doi.org/10.1182/blood-2006-11-056028
Kantarjian, Hagop ; Pasquini, Ricardo ; Hamerschlak, Nelson ; Rousselot, Philippe ; Holowiecki, Jerzy ; Jootar, Saengsuree ; Robak, Tadeusz ; Khoroshko, Nina ; Masszi, T. ; Skotnicki, Aleksander ; Hellmann, Andrzej ; Zaritsky, Andrey ; Golenkov, Anatoly ; Radich, Jerald ; Hughes, Timothy ; Countouriotis, Athena ; Shah, Neil. / Dasatinib or high-dose imatinib for chronic-phase chronic myeloid leukemia after failure of first-line imatinib : A randomized phase 2 trial. In: Blood. 2007 ; Vol. 109, No. 12. pp. 5143-5150.
@article{3edc773043824806b4b582dd3070f8ec,
title = "Dasatinib or high-dose imatinib for chronic-phase chronic myeloid leukemia after failure of first-line imatinib: A randomized phase 2 trial",
abstract = "Therapeutic options for chronic myelogenous leukemia (CML) resistant to 400 to 600 mg imatinib are limited. Escalating imatinib doses may overcome resistance. Dasatinib, a significantly more potent inhibitor of BCR-ABL, is safe and effective in this population. Patients with imatinib-resistant chronic-phase (CP) CML were randomized 2:1 to 140 mg dasatinib (n = 101) or 800 mg imatinib (n = 49). With a median follow up of 15 months, complete hematologic responses were observed in 93{\%} and 82{\%} of patients receiving dasatinib and high-dose imatinib (P = .034), respectively. Dasatinib resulted in higher major cytogenetic response rates (52{\%}) than high-dose imatinib (33{\%}) (P = .023); this included complete cytogenetic response in 40{\%} and 16{\%} (P = .004). Major molecular responses were also more frequent with dasatinib (16{\%} versus 4{\%}; P = 0.038). Treatment failure (hazard ratio [HR], 0.16; P <.001) and progression-free survival (HR, 0.14;P",
author = "Hagop Kantarjian and Ricardo Pasquini and Nelson Hamerschlak and Philippe Rousselot and Jerzy Holowiecki and Saengsuree Jootar and Tadeusz Robak and Nina Khoroshko and T. Masszi and Aleksander Skotnicki and Andrzej Hellmann and Andrey Zaritsky and Anatoly Golenkov and Jerald Radich and Timothy Hughes and Athena Countouriotis and Neil Shah",
year = "2007",
month = "6",
day = "15",
doi = "10.1182/blood-2006-11-056028",
language = "English",
volume = "109",
pages = "5143--5150",
journal = "Blood",
issn = "0006-4971",
publisher = "American Society of Hematology",
number = "12",

}

TY - JOUR

T1 - Dasatinib or high-dose imatinib for chronic-phase chronic myeloid leukemia after failure of first-line imatinib

T2 - A randomized phase 2 trial

AU - Kantarjian, Hagop

AU - Pasquini, Ricardo

AU - Hamerschlak, Nelson

AU - Rousselot, Philippe

AU - Holowiecki, Jerzy

AU - Jootar, Saengsuree

AU - Robak, Tadeusz

AU - Khoroshko, Nina

AU - Masszi, T.

AU - Skotnicki, Aleksander

AU - Hellmann, Andrzej

AU - Zaritsky, Andrey

AU - Golenkov, Anatoly

AU - Radich, Jerald

AU - Hughes, Timothy

AU - Countouriotis, Athena

AU - Shah, Neil

PY - 2007/6/15

Y1 - 2007/6/15

N2 - Therapeutic options for chronic myelogenous leukemia (CML) resistant to 400 to 600 mg imatinib are limited. Escalating imatinib doses may overcome resistance. Dasatinib, a significantly more potent inhibitor of BCR-ABL, is safe and effective in this population. Patients with imatinib-resistant chronic-phase (CP) CML were randomized 2:1 to 140 mg dasatinib (n = 101) or 800 mg imatinib (n = 49). With a median follow up of 15 months, complete hematologic responses were observed in 93% and 82% of patients receiving dasatinib and high-dose imatinib (P = .034), respectively. Dasatinib resulted in higher major cytogenetic response rates (52%) than high-dose imatinib (33%) (P = .023); this included complete cytogenetic response in 40% and 16% (P = .004). Major molecular responses were also more frequent with dasatinib (16% versus 4%; P = 0.038). Treatment failure (hazard ratio [HR], 0.16; P <.001) and progression-free survival (HR, 0.14;P

AB - Therapeutic options for chronic myelogenous leukemia (CML) resistant to 400 to 600 mg imatinib are limited. Escalating imatinib doses may overcome resistance. Dasatinib, a significantly more potent inhibitor of BCR-ABL, is safe and effective in this population. Patients with imatinib-resistant chronic-phase (CP) CML were randomized 2:1 to 140 mg dasatinib (n = 101) or 800 mg imatinib (n = 49). With a median follow up of 15 months, complete hematologic responses were observed in 93% and 82% of patients receiving dasatinib and high-dose imatinib (P = .034), respectively. Dasatinib resulted in higher major cytogenetic response rates (52%) than high-dose imatinib (33%) (P = .023); this included complete cytogenetic response in 40% and 16% (P = .004). Major molecular responses were also more frequent with dasatinib (16% versus 4%; P = 0.038). Treatment failure (hazard ratio [HR], 0.16; P <.001) and progression-free survival (HR, 0.14;P

UR - http://www.scopus.com/inward/record.url?scp=34249074686&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=34249074686&partnerID=8YFLogxK

U2 - 10.1182/blood-2006-11-056028

DO - 10.1182/blood-2006-11-056028

M3 - Article

C2 - 17317857

AN - SCOPUS:34249074686

VL - 109

SP - 5143

EP - 5150

JO - Blood

JF - Blood

SN - 0006-4971

IS - 12

ER -